TrialOncotarget2015

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.

Eric Assenat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.